Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mainz Biomed N.V. - Ordinary Shares
(NQ:
MYNZ
)
0.3590
+0.0118 (+3.40%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Mainz Biomed N.V. - Ordinary Shares
< Previous
1
2
3
4
5
6
Next >
Mainz Biomed's (NASDAQ: MYNZ) Cutting-Edge Colorectal Cancer Test Applies For FDA Breakthrough Status
July 31, 2024
Mainz Biomed's (NASDAQ: MYNZ) Cutting-Edge Colorectal Cancer Test Applies For FDA Breakthrough Status
Via
News Direct
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
July 30, 2024
The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical companies like Pfizer Inc (NYSE: PFE)...
Via
Benzinga
Exposures
COVID-19
Pfizer And Mainz Provide Examples Of Using Emerging Technology For Good
July 10, 2024
This week, Pfizer Inc (NYSE: PFE) revealed a new collaboration to unlock new therapeutic approaches. Its smaller European industry peer specialized in early detection of cancer, Mainz Biomed N.V.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
July 09, 2024
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday morning!
Via
InvestorPlace
Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
July 09, 2024
Via
Benzinga
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 08, 2024
Via
Benzinga
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
July 02, 2024
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens...
Via
Benzinga
Exposures
COVID-19
Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
June 26, 2024
On Tuesday, Merck Group revealed an unexpected decision to end a Phase III trial of its cancer drug Xevinapant. This move threatens to undermine confidence the research abilities of the Darmstadt,...
Via
Benzinga
Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks
June 21, 2024
Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks
Via
News Direct
Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate
June 05, 2024
Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate
Via
News Direct
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
June 04, 2024
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial. On Monday, Moderna (NASDAQ: MRNA) and Merck & Co...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
June 04, 2024
Via
Benzinga
Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
May 29, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
May 29, 2024
It's time to start the day with a breakdown of the biggest pre-market stock movers traders are going to want to watch on Wednesday morning!
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 17, 2024
The final day of trading this week is here and we have the biggest pre-market stock movers worth watching on Friday morning!
Via
InvestorPlace
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
May 16, 2024
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,...
Via
Benzinga
mRNA Is Promising A Breakthrough In Fighting Cancer
April 29, 2024
When it comes to cancer, there’s innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COVID-19 era as it...
Via
Benzinga
Exposures
COVID-19
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
April 10, 2024
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE:
Via
Benzinga
MYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023
April 09, 2024
MYNZ stock results show that Mainz Biomed beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
April 02, 2024
Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for saving the world from an unforeseen pandemic.
Via
Benzinga
Exposures
COVID-19
Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening
February 28, 2024
When it comes to cancer, one cannot overestimate the importance of early detection. Especially when it comes to colorectal and endometrial cancer that even big pharma companies don’t have a good track...
Via
Benzinga
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
February 22, 2024
Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several...
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
February 07, 2024
On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine...
Via
Benzinga
2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge
February 02, 2024
--News Direct--
Via
News Direct
Topics
Death
Exposures
Death
Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle
February 01, 2024
On Tuesday, Pfizer Inc (NYSE: PFE) reported mixed results for its fourth quarter. Last year, Pfizer has responded to concerns related to its COVID-19 products being the rearview mirror with a...
Via
Benzinga
Exposures
COVID-19
2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge
February 01, 2024
The global population is experiencing a scary increase in colorectal cancer, especially among young people. Colorectal cancer (CRC) diagnoses have been steadily rising since the 1990s; in 1995 the...
Via
Benzinga
Topics
Death
Exposures
Death
2024 Marks a New Era Of Pharmaceutical Innovation
January 09, 2024
With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned...
Via
Benzinga
Exposures
COVID-19
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer
December 29, 2023
During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc.
Via
Benzinga
Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study
December 19, 2023
Via
Benzinga
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 05, 2023
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.